Address1 (Address1)
Donepezil Tablet
Product Images NDC 50090-2627
15 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil (NDC 50090-2627). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Address2 (Address2)
Donepezilfigure10 (Donepezilfigure10)
A cumulative percentage graph showing the proportion of patients versus ADCS-ADL change from baseline, comparing Donepezil Hydrochloride 10 mg/day with placebo. The graph includes two curves representing treatment groups and a vertical line marking a specific baseline change value.*
Donepezilfigure8 (Donepezilfigure8)
A cumulative percentage graph comparing the change from baseline in SIB (Severe Impairment Battery) scores between Donepezil hydrochloride 10 mg/day and placebo groups. The x-axis shows SIB change from baseline, and the y-axis represents the cumulative percentage of patients, highlighting differences in treatment effects over a range of SIB score changes.*
Figure1 (Figure1)
A line graph showing ADAS-cog mean change from baseline over weeks of drug treatment for Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and Placebo. The y-axis represents clinical improvement to decline, while the x-axis shows weeks from 0 to 30. Error bars indicate standard error (SE).*
Figure2 (Figure2)
A cumulative percentage plot showing change from baseline in ADAS-cog scores for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo treatment groups. The x-axis represents change from baseline, and the y-axis shows cumulative percentage of patients. The graph includes data points at 7 points, 4 points, and no change, with a small table summarizing percentage improvement by treatment group.*
Figure3 (Figure3)
A bar graph comparing the percentages of patients with various CIBIC-Plus ratings after treatment with Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo. The ratings include markedly improved, minimally improved, no change, minimally worse, moderately worse, and markedly worse.*
Figure4 (Figure4)
A line graph showing ADAS-cog score changes from baseline over 15 weeks of drug treatment, comparing Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo groups. The y-axis indicates clinical improvement or decline, with Donepezil 10 mg/day showing the greatest clinical improvement by week 15.*
Figure5 (Figure5)
A cumulative percentage graph showing patients' change from baseline in ADAS-cog scores for Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups. The graph includes vertical lines at 7, 4 points, and no change, with a table summarizing percentage changes in ADAS-cog scores for each treatment group.*
Figure6 (Figure6)
A bar chart comparing the CIBIC-plus Rating distribution for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The x-axis shows various rating categories from Markedly Improved to Markedly Worse, and the y-axis shows the percentage of patients in each category.*
Figure7 (Figure7)
A line graph showing SIB (Severe Impairment Battery) change from baseline over six months of drug treatment. It compares Donepezil Hydrochloride 10 mg/day and placebo, depicting clinical improvement and decline on the vertical axis and months of treatment on the horizontal axis.*
Figure9 (Figure9)
A line graph showing the mean change from baseline in ADCS-ADL scores over 6 months of drug treatment. Two lines compare Donepezil Hydrochloride 10 mg/day and placebo, with Donepezil showing less clinical decline than placebo over time. The vertical axis is labeled with clinical improvement and decline, and the horizontal axis shows months of treatment.*
Label Image (Lbl500902627)
Donepezil Hydrochloride 10 mg film-coated tablet label from A-S Medication Solutions. The label indicates the product contains 90 tablets, with storage instructions to keep between 68 to 77 degrees Fahrenheit. The lot number and NDC 50090-2627-0 are visible, along with a QR code for the package insert.*
Label Image (Lbl500902910)
Donepezil hydrochloride 5 mg tablet label from A-S Medication Solutions. The label displays product number 6310-0, storage instructions to keep between 68-77 degrees Fahrenheit, and indicates the package contains 90 tablets. It includes a QR code and packaging location information for Libertyville, Illinois.*
Structure (Structure)
Chemical structure of donepezil hydrochloride showing the molecular arrangement with methoxy groups, a piperidine ring, and a benzyl group attached to the core structure.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
